Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today that the company’s late-breaker oral presentation at The International Liver Congress™ 2019, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 10-14,...
TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in osteoarthritis, pain management, ophthalmology and oncology,...
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced Ovaprene’s inclusion in a presentation to physicians on the latest forms of novel contraception. Ovaprene is Daré’s clinical stage, non-hormonal vaginal ring designed to...
Demonstrated statistically significant reduction in daily smoking compared to active comparator (p=0.0016) Trial conducted in collaboration with Duke University NEW YORK, April 15, 2019 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Interim safety results and early efficacy signals with HepaStem bode well for subsequent confirmatory trials in ACLF and provide valuable insights for imminent start of clinical evaluation in NASH Promethera Biosciences SA, a global innovator in cell-based medicines...
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first presentation of results from ASPECT-NP, a randomized, double-blind, multi-center Phase 3 clinical trial evaluating the efficacy and safety of ZERBAXA ® (ceftolozane and...
Email
Text